Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery

Expert Opinion on Pharmacotherapy
Daniele Roberto GiacobbeClaudio Viscoli

Abstract

Patients undergoing open-heart surgery may suffer from postoperative complications, including severe infections. Antimicrobials to treat infectious complications in this population should be selected thoughtfully, taking into account three different and fundamental issues: (i) the site of infection; (ii) the suspected or proven causative agent and its susceptibility pattern; and (iii) the risk of suboptimal pharmacokinetic characteristics and potential toxicity of the chosen drug/s. The present narrative review summarizes the current and future antimicrobial options for the treatment of infections developing after open-heart surgery. The pharmacological treatment of infections developing in cardiac surgery patients poses peculiar challenges, including the need for an active empirical therapy for severe events such as bloodstream infections, deep sternal wound infections, or early-onset postoperative prosthetic endocarditis. In addition, the risk for multidrug-resistant pathogens should also be taken into account in endemic areas. A multidisciplinary evaluation on a patient-by-patient basis, deeply involving infectious diseases specialists and cardiothoracic surgeons, remains essential for appropriately balancing both short-term...Continue Reading

References

May 1, 1975·The Annals of Thoracic Surgery·R G NorenbergT Takaro
Oct 1, 1975·The Surgical Clinics of North America·F G Estafanous
Jun 1, 1991·The Journal of Hospital Infection·R Freeman
Dec 1, 1991·Mayo Clinic Proceedings·R C Walker, A J Wright
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P CanepariG Satta
Feb 1, 1990·Antimicrobial Agents and Chemotherapy·J BrajtburgG Medoff
Sep 1, 1986·The Annals of Thoracic Surgery·R M Nelson, D J Dries
Jan 1, 1985·Pharmacology & Therapeutics·D J Tipper
May 1, 1970·The American Journal of Cardiology·R B Shafer, W H Hall
Sep 10, 1983·British Medical Journal·J Moore-GillonI Phillips
Feb 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M C FariñasJ González-Macías
Nov 1, 1994·Journal of the American College of Cardiology·P A McKenneyR Davidoff
Mar 1, 1996·The Annals of Thoracic Surgery·R M El Oakley, J E Wright
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·S M SwaneyD L Shinabarger
May 4, 1999·Journal of Cardiac Surgery·M K GölK Bayazit
Dec 20, 1999·Drugs·D C Hooper
Jan 22, 2000·BMJ : British Medical Journal·C PopeN Mays
Jan 20, 2000·Antimicrobial Agents and Chemotherapy·J OnishiM B Kurtz
Jul 6, 2000·The Annals of Thoracic Surgery·S M GordonD M Cosgrove
Sep 27, 2000·American Journal of Surgery·S D HanesB A Boucher
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·F B OlesonF P Tally
Mar 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Mekontso-DessapD Loisance
Dec 21, 2002·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Daisy JonkersEllen Stobberingh
May 10, 2003·American Journal of Respiratory and Critical Care Medicine·Muriel FartoukhChristian Brun-Buisson
Jul 15, 2003·Clinical Microbiology Reviews·Sergei B Vakulenko, Shahriar Mobashery
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Jared A SilvermanHoward M Shapiro
Oct 22, 2003·Circulation·Larry M BaddourUNKNOWN AHA
Oct 30, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elyse SeltzerUNKNOWN Dalbavancin Skin and Soft-Tissue Infection Study Group
Dec 11, 2003·Chest·Argyris S MichalopoulosSpyros D Mentzelopoulos
Dec 11, 2003·The Journal of Thoracic and Cardiovascular Surgery·Tomaso BottioGino Gerosa
May 1, 2004·Critical Reviews in Microbiology·A A ShahA Hameed
Sep 24, 2004·Nursing·Susan Simmons Holcomb
Dec 29, 2004·International Journal of Antimicrobial Agents·Christine BuckWilhem Dieter Paar
Mar 19, 2005·Critical Care : the Official Journal of the Critical Care Forum·Kevin B LauplandDeirdre L Church
May 18, 2005·The Journal of Infectious Diseases·Jared A SilvermanJeff Alder
Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vincent T Andriole
Jul 5, 2005·Expert Opinion on Investigational Drugs·F P TallyF B Oleson
Jul 26, 2005·The Journal of Antimicrobial Chemotherapy·George A Pankey

❮ Previous
Next ❯

Citations

May 15, 2020·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalCristina Elena Martí-Amarista
Aug 9, 2020·Open Forum Infectious Diseases·Daniele Roberto GiacobbeMatteo Bassetti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Sebastian ColombierDenis A Berdajs
© 2022 Meta ULC. All rights reserved